Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01928329 · ClinicalTrials.gov registry record · Phase 2
A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes
A Phase 2 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 79
- Enrollment target
NCT01928329 is a Phase 2 study that has completed, run by Yale University. The registered enrollment target is 79 participants.
The verdict
NCT01928329, a Phase 2 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 79 participants
- Enrollment target
Study Summary
The goal of the proposed pilot study is to determine whether glucose control can be improved with Bydureon treatment in patients with type I diabetes (T1D)
Interventions
- DRUG Placebo
- DRUG Exenatide (Bydureon®)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2013-09 |
| Est. Completion | 2019-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01928329
The ClinicalTrials.gov registry entry for NCT01928329 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01928329 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01928329 about?
NCT01928329 is a clinical study titled "A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes". The goal of the proposed pilot study is to determine whether glucose control can be improved with Bydureon treatment in patients with type I diabetes (T1D)
What is the current status of trial NCT01928329?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 79 participants. The study started on 2013-09. Estimated completion is 2019-08.
What interventions are being tested in trial NCT01928329?
The interventions under investigation include: Placebo (DRUG), Exenatide (Bydureon®) (DRUG).
Who is sponsoring clinical trial NCT01928329?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.